Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway

Ana Catarina Lunz Macedo, Lourdes Isaac, Ana Catarina Lunz Macedo, Lourdes Isaac

Abstract

The complement system plays an important role in the innate and acquired immune response against pathogens. It consists of more than 30 proteins found in soluble form or attached to cell membranes. Most complement proteins circulate in inactive forms and can be sequentially activated by the classical, alternative, or lectin pathways. Biological functions, such as opsonization, removal of apoptotic cells, adjuvant function, activation of B lymphocytes, degranulation of mast cells and basophils, and solubilization and clearance of immune complex and cell lysis, are dependent on complement activation. Although the activation of the complement system is important to avoid infections, it also can contribute to the inflammatory response triggered by immune complex deposition in tissues in autoimmune diseases. Paradoxically, the deficiency of early complement proteins from the classical pathway (CP) is strongly associated with development of systemic lupus erythematous (SLE) - mainly C1q deficiency (93%) and C4 deficiency (75%). The aim of this review is to focus on the deficiencies of early components of the CP (C1q, C1r, C1s, C4, and C2) proteins in SLE patients.

Keywords: C1q; C2; C4; SLE; complement deficiency; lupus.

References

    1. Liu C-C, Ahearn JM. Complement and systemic lupus erythematosus. 7th ed In: Wallace DJ, Hahn BH, editors. Dubois’ Lupus Erythematosus. (Chap. 13), Philadelphia: Lippincott Williams & Wilkins; (2007). p. 214–35.
    1. Grammatikos AP, Tsokos GC. Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends Mol Med (2012) 18:101–8.10.1016/j.molmed.2011.10.005
    1. Ippolito A, Wallace DJ, Gladman D, Fortin PR, Urowitz M, Werth V, et al. Auto-antibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus (2011) 20:250–5.10.1177/0961203310385738
    1. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 64(8):2677–86.10.1002/art.34473
    1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 25(11):1271–7.10.1002/art.1780251101
    1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 40(9):1725.10.1002/art.1780400928
    1. Pieterse E, van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol (2014) 5:164.10.3389/fimmu.2014.00164
    1. Botto M, Walport MJ. C1q autoimmunity and apotosis. Immunobiology (2002) 205:396–406.10.1078/0171-2985-00141
    1. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med (2010) 16(2):47–57.10.1016/j.molmed.2009.12.005
    1. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum (2010) 39(4):257.10.1016/j.semarthrit.2008.10.007
    1. Fernandez M, Alarcón GS, Calvo-Alen J, Andrade R, McGwin G, Jr, Vilá LM, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum (2007) 57:576–84.10.1002/art.22672
    1. McCarty DJ, Manzi S, Medsger TA, Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum (1995) 38:1260–70.10.1002/art.1780380914
    1. Malattia C, Martini A. Pediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol (2013) 27:351–62.10.1016/j.berh.2013.07.007
    1. Morgan TA, Watson L, McCann LJ, Beresford MW. Children and adolescents with SLE: not just little adults. Lupus (2013) 22:1309–19.10.1177/0961203313502863
    1. Tarr T, Dérfalvi B, Győri N, Szántó A, Siminszky Z, Malik A, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus (2015) 24:796–803.10.1177/0961203314563817
    1. Choi JH, Park DJ, Kang JH, Yim YR, Lee KE, Lee JW, et al. Comparison of clinical and serological differences among juvenile-, adult-, and late-onset systemic lupus erythematosus in Korean patients. Lupus (2015) 24:1342–9.10.1177/0961203315591024
    1. Papadimitraki ED, Isenberg DA. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol (2009) 5:391–403.10.1586/eci.09.29
    1. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum (1992) 35(3):311–8.10.1002/art.1780350310
    1. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus complement deficiency and apoptosis. Adv Immunol (2000) 76:227–324.10.1016/S0065-2776(01)76021-X
    1. Barilla-LaBarca ML, Atkinson JP. Rheumatic syndromes associated with complement deficiency. Curr Opin Rheumatol (2003) 15:55–60.10.1097/00002281-200301000-00010
    1. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology (1998) 199:265–85.10.1016/S0171-2985(98)80032-6
    1. Kallel-Sellami M, Baili-Klila L, Zerzeri Y, Laadhar L, Blouin J, Abdelmalek R, et al. Hereditary complement deficiency and lupus: report of four Tunisian cases. Ann N Y Acad Sci (2007) 1108:197–202.10.1196/annals.1422.022
    1. Isenman DE, Kells DI, Cooper NR, Muller-Eberhard HJ, Pangburn MK. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 20(15):4458–67.10.1021/bi00518a034
    1. Isenman DE, Kells DI. Conformational and functional changes in the fourth component of human complement producer by nucleophilic modification and by proteolysis with C1s-. Biochemistry (1982) 21(6):1109–17.10.1021/bi00535a001
    1. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 145(3):856–67.10.1084/jem.154.3.856
    1. Pangburn MK, Müller-Eberhard HJ. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci (1983) 421:291–8.10.1111/j.1749-6632.1983.tb18116.x
    1. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A (1980) 77(10):5764–8.10.1073/pnas.77.10.5764
    1. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 142:856–63.10.1084/jem.142.4.856
    1. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 76(11):5867–71.10.1073/pnas.76.11.5867
    1. Lepow IH. Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, properdin, and scientific controversy. J Immunol (1980) 125(2):471–5.
    1. Müller-Eberhard HJ, Schreiber RD. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 29:1–53.10.1016/S0065-2776(08)60042-5
    1. Pangburn MK, Müller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol (1984) 7(2–3):163–92.10.1007/BF01893019
    1. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity: I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science (1954) 120:279–85.10.1126/science.120.3112.279
    1. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 179:2600–8.10.4049/jimmunol.179.4.2600
    1. Kemper C, Hourcade DE. Properdin: new roles in pattern recognition and target clearance. Mol Immunol (2008) 45(16):4048–56.10.1016/j.molimm.2008.06.034
    1. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol (2010) 28:131–55.10.1146/annurev-immunol-030409-101250
    1. Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity (2001) 15(1):127–35.10.1016/S1074-7613(01)00161-3
    1. Fujita T, Matsushita M, Endo Y. The lectin – complement pathway – its role in innate immunity and evolution. Immunol Rev (2004) 198:185–202.10.1111/j.0105-2896.2004.0123.x
    1. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med (1992) 176(6):1497–502.10.1084/jem.176.6.1497
    1. Matsushita M, Endo Y, Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol (2000) 164(5):2281–4.10.4049/jimmunol.164.5.2281
    1. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature (1997) 386:506–10.10.1038/386506a0
    1. Walport MJ. First of two parts. N Engl J Med (2001) 344(14):1058–66.10.1056/NEJM200104053441406
    1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 11(9):785–97.10.1038/ni.1923
    1. Mayer MM. Mechanism of cytolysis by complement. Proc Natl Acad Sci U S A (1972) 69(10):2954–8.10.1073/pnas.69.10.2954
    1. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol (1999) 19(3):173–98.10.1615/CritRevImmunol.v19.i3.10
    1. Whaley K, Lemercier C. The complement system. In: Sim E, editor. Humoral Factors. (Chap. 5), Oxford: Oxford University Press; (1993). p. 121–50.
    1. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2007) 7(1):9–18.10.1038/nri1994
    1. Rooijakkers SH, van Strijp JA. Bacterial complement evasión. Mol Immunol (2007) 44:23–32.10.1016/j.molimm.2006.06.011
    1. Zipfel PF, Würzner R, Skerka C. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol Immunol (2007) 44(16):3850–7.10.1016/j.molimm.2007.06.149
    1. da Silva WD, Eisele JW, Lepow IH. Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C3. J Exp Med (1967) 126(6):1027–48.10.1084/jem.126.6.1027
    1. Osler AG, Randall HG, Hill BM, Ovary Z. Studies on the mechanism of hypersensitivity phenomena. III. The participation of complement in the formation of anaphylatoxin. J Exp Med (1959) 110(2):311–39.10.1084/jem.110.2.311
    1. Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflamatory molecule? Re-evaluating the evidence and the myth. J Immunol (2015) 194:3542–8.10.4049/jimmunol.1403068
    1. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 271(5247):348–50.10.1126/science.271.5247.348
    1. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol (2004) 4(10):825–31.10.1038/nri1456
    1. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 158(10):4525–8.
    1. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med (2000) 192(3):359–66.10.1084/jem.192.3.359
    1. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology (1999) 42:47–52.10.1016/S0162-3109(99)00018-1
    1. Flierman R, Daha MR. The clearance of apoptotic cells by complement. Immunobiology (2007) 212(4–5):363–70.10.1016/j.imbio.2006.11.005
    1. Bouts YM, Wolthuis DF, Dirkx MF, Pieterse E, Simons EM, Van Boekel AM, et al. Apoptosis and NET formation in the pathogenesis of SLE. Autoimmunity (2012) 45:597–601.10.3109/08916934.2012.719953
    1. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extra cellular trap degradation is associated whit lupus nephritis. Proc Natl Acad Sci U S A (2010) 107:9813–8.10.1073/pnas.0909927107
    1. Skiljevic D, Jeremic I, Nikolic M, Andrejevic S, Sefik-Bukilica M, Stojimirovic B, et al. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement. Clin Chem Lab Med (2013) 51:1083–91.10.1515/cclm-2012-0521
    1. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 41:1241–50.10.1002/1529-0131(199807)41:7<1241::AID-ART15>;2-H
    1. Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum (2010) 39:491–503.10.1016/j.semarthrit.2008.11.002
    1. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, et al. Disease-associated loss of erytrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving auto-antibodies and/or complement activation. J Immunol (1985) 135:2005–14.
    1. Hosszu KK, Valentino A, Ji Y, Matkovic M, Pednekar L, Rehage N, et al. Cell surface expression and function of the macromolecular C1 complex on the surface of human monocytes. Front Immunol (2012) 3:38.10.3389/fimmu.2012.00038
    1. Ghebrehiwet B, Hosszu KK, Valentino A, Ji Y, Peerschke EIB. Monocyte expressed macromolecular C1 and C1q receptors as molecular sensors of danger: implications in SLE. Front Immunol (2014) 5:278.10.3389/fimmu.2014.00278
    1. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 191:411–6.10.1084/jem.191.3.411
    1. Chen A, Gaddipati S, Volkman DJ, Peerschke EIB, Ghebrehiwet B. Human T cells possess specific receptors for C1q: role in activation and proliferation. J Immunol (1994) 153:1430–40.
    1. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest (2000) 106(10):1239–49.10.1172/JCI10323
    1. Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, et al. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol (2015) 35(2):199–205.10.1007/s10875-015-0137-5
    1. Arason GJ, Jorgensen GH, Ludviksson BR. Primary immunodeficiency and autoimmunity: lessons from human diseases. Scand J Immunol (2010) 71:317–28.10.1111/j.1365-3083.2010.02386.x
    1. Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol (2014) 61:110–7.10.1016/j.molimm.2014.06.030
    1. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun (2010) 34:276–86.10.1016/j.jaut.2009.11.014
    1. Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and autoimmunity. Ann N Y Acad Sci (1997) 815:267–81.10.1111/j.1749-6632.1997.tb52069.x
    1. Jesus AA, Liphaus BL, Silva CA, Bando SY, Andrade LEC, Coutinho A, et al. Complement and antibody primary immunodeficiency in juvenile systemic lupus erythematosus patients. Lupus (2011) 20:1275–84.10.1177/0961203311411598
    1. Bhattad S, Rawat A, Gupta A, Suri D, Garg R, de Boer M, et al. Early complement component deficiency in a single-centre cohort of pediatric onset lupus. J Clin Immunol (2015) 35(8):777–85.10.1007/s10875-015-0212-y
    1. Stegert M, Bock M, Trendelenburg M. Clinical presentation of human C1q deficiency: how much of a lupus? Mol Immunol (2015) 67:3–11.10.1016/j.molimm.2015.03.007
    1. Mayilyan KR. Complement genetics, deficiencies, and disease associations. Protein Cell (2012) 3:487–96.10.1007/s13238-012-2924-6
    1. Amano MT, Ferriani VP, Florido MP, Reis ES, Delcolli MI, Azzolini AE, et al. Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Mol Immunol (2008) 45(6):1693–702.10.1016/j.molimm.2007.09.034
    1. Jlajla H, Sellami MK, Sfar I, Laadhar L, Zerzeri Y, Abdelmoula MS, et al. New C1q mutation in a Tunisian family. Immunobiology (2014) 219:241–6.10.1016/j.imbio.2013.10.010
    1. Olsson R, Hagelberg S, Ringden O, Truedsson L, Åhlin A. Allogeneic haematopoietic stem cell transplantation restores complement function in human hereditary C1q deficiency. Bone Marrow Transplant (2013) 217(2012):1129–222.10.1016/j.imbio.2012.08.022
    1. Arkwright PD, Riley P, Hughes SM, Alachkar H, Wynn RF. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol (2014) 133:265–7.10.1016/j.jaci.2013.07.035
    1. Olsson R, Hagelberg S, Schiller B, Ringden O, Truedsson L, Åhlin A. Allogeneic haematopoietic stem cell transplantation in the treatment for human C1q deficiency – the Karolinska experience. Bone Marrow Transpl (2015) 50:S489.10.1097/TP.0000000000000975
    1. Beurskens FJ, van Schaarenburg RA, Trouw LA. C1q, antibodies and anti-C1q autoantibodies. Mol Immunol (2015) 68(1):6–13.10.1016/j.molimm.2015.05.010
    1. Fremeaux-Bacchi V, Weiss L, Demouchy C, Blouin J, Kazatchkine MD. Auto-antibodies to the collagen-like region of C1q are strongly associated with classical pathway mediated hypocomplementemia in systemic lupus erythematosus. Lupus (1996) 5:216.10.1177/096120339600500309
    1. Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G. Anti-C1q auto-antibodies in lupus nephritis. Ann N Y Acad Sci (2009) 1173:47–51.10.1111/j.1749-6632.2009.04746.x
    1. O’Neil KM. Complement deficiency. Clin Rev Allergy Immunol (2000) 19:83.10.1385/CRIAI:19:2:83
    1. Laich A, Sim RB. Cross-talk between the human complement classical and alternative pathways: evidence for a C4bBb “hybrid” C3 convertase. Mol Immunol (2001) 38:105.
    1. Jonsson G, Sjoholm AG, Truedsson L, Bengtsson AA, Braconier JH, Sturfelt G. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology (Oxford) (2007) 46:1133–9.10.1093/rheumatology/kem023
    1. Wetsel RA, Kulics J, Lokki ML, Kiepiela P, Akama H, Johnson CA, et al. Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189→Phe; Gly444→Arg) cause impaired C2 secretion. J Biol Chem (1996) 271(10):5824–31.10.1074/jbc.271.10.5824
    1. Yang Y, Lhotta K, Chung EK, Eder P, Neumair F, Yu CY. Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus. J Immunol (2004) 173:2803–14.10.4049/jimmunol.173.4.2803
    1. Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, et al. Gene copy-number variation and associated polymorphisms of complement component c4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet (2007) 80:1037–54.10.1086/518257
    1. Schaarenburg RA, Schejbel L, Truedsson L, Topaloglu R, Al-Mayouf SM, Riordan A, et al. Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. J Autoimmun (2015) 62:39–44.10.1016/j.jaut.2015.06.002

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel